The Pharmacogenomic Era: Promise for Personalizing Attention Deficit Hyperactivity Disorder Therapy

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 2, 2008, Pages 475-490

  Stein, Mark A ^a   McGough, James J ^b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC ALPHA 2A RECEPTOR; ALPHA ADRENERGIC RECEPTOR; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; NORADRENALIN TRANSPORTER; NOREPINEPHRINE TRANSPORT PROTEIN 1; PLACEBO; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COMPREHENSION; DRUG DOSE TITRATION; GENOME; HUMAN; MEDICAL RESEARCH; METABOLISM; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOTRANSFORMATION; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; GENETIC MARKERS; HUMANS; PHARMACOGENETICS; RECEPTORS, NEUROTRANSMITTER; TREATMENT OUTCOME;

EID: 39449094563     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2007.11.009     Document Type: Review

References (62)

1. Prince J. Pharmacotherapy of attention-deficit hyperactivity in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 15 (2006) 15-30
2. Faraone S.V., Biederman J., Spencer T.J., et al. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 8 (2006) 4
3. Charach A., Ickowicz A., and Schachar R. Stimulant treatment over five years; adherence, effectiveness, and adverse events. J Am Acad Child Adolesc Psychiatry 43 (2004) 559-567
4. Schachar R.J., and Tannock R. Childhood hyperactivity and psychostimulants: a review of extended treatment studies. J Child Adolesc Psychopharmacol 3 (1993) 81-97
5. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 113 (2004) 754-761
6. Faraone S.V., and Doyle A.E. The nature and heritability of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 10 (2001) 299-316
7. Faraone S.V., Perlis R., Doyle A.E., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57 (2005) 1313-1323
8. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 409 (2001) 860-861
9. McGough J.J. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 57 (2005) 1367-1373
10. Polanczyk G., Zeni C., Genro J., et al. Attention-deficit/hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics 6 (2005) 225-234
11. Weber W.W. Pharmacogenetics (1997), Oxford Press, New York
12. Aitchison K.J., Gill M., et al. Pharmacogenetics in the postgenomic era. In: Plomin R., Devries J., and Craig I. (Eds). Behavioral genetics in the postgenomic era (2003), American Psychological Association, Washington, DC 335-361
13. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet 356 (2000) 1667-1671
14. Staddon S., Aranz M.J., Mancama D., et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology 162 (2002) 18-23
15. Masellis M., Basile V., Muglia P., et al. Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder. Behav Brain Res 130 (2002) 85-90
16. Sklar P. Principles of haplotype mapping and potential applications to attention-deficit hyperactivity disorder. Biol Psychiatry 57 (2005) 1357-1366
17. Goldstein D.B. Pharmacogenetics in the laboratory and the clinic. N Engl J Med 348 (2003) 553-556
18. Cook E.H., Stein M.A., Krasowski M.D., et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56 (1995) 993-998
19. Melega W.P., Williams A.C., Schmitz D.A., et al. Pharmacokinetic and pharmacodynamic analysis of the actions of d-amphetamine and d-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274 (1995) 90-96
20. Volkow N.D., Wang G., Fowler J.S., et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 161 (2004) 1173-1180
21. Spencer T.J., Biederman J., Madras B.K., et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 57 (2005) 1293-1300
22. VanNess S.H., Owens M.J., and Kilts C.D. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6 (2005) 55
23. Winsberg B.G., and Comings D.E. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adoelsc Psychiatry 38 (1999) 1474-1477
24. Roman T., Szobot C., Martine S., et al. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12 (2002) 497-499
25. Cheon K.A., Ryu Y.H., Kim J.W., et al. The homozygosity for the 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15 (2005) 95-101
26. Kirley A., Lowe N., Hawi A., et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet 121B (2003) 50-54
27. Stein M.A., Waldman I.D., Sarampote C.S., et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 30 (2005) 1374-1382
28. Joober R., Grizenko N., Sengupta S., et al. Dopamine transporter 3′-UTR VNTR genotype and ADHD: a pharmaco-behavioral genetic study with methylphenidate. Neuropsychopharmacology 32 (2006) 1370-1376
29. Lott D., Kim S., Cook E., et al. Dopamine transporter genotype and amphetamine response. Neuropsychopharmacology 30 (2003) 602-609
30. Van der Meulen E.M., Bakker S.C., Pauls D.L., et al. High sibling correlation on methylphenidate response but no association with DAT1-10R and DRD4-7 alleles in Dutch sibpairs with ADHD. J Child Psychol Psychiatry 46 (2005) 1074-1080
31. Langley K., Turic D., Peirce T.R., et al. No support for association between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet 139B (2005) 7-10
32. Zeni C.P., Guimarães A.P., Polanczyk G.V., et al. No significant association between response to methylphenidate and genes of the dopaminergic serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 144 (2007) 391-394
33. McGough J.J., McCracken J.T., Swanson J., et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45 (2006) 1314-1322
34. Mick E., Biederman J., Spencer T., et al. Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet 141 (2006) 890-894
35. Asghari V., Sanyal S., Buchwaldt S., et al. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65 (1995) 1157-1165
36. Van Tol H.H., Wu C.M., Guan H.C., et al. Multiple dopamine D4 receptor variants in the human population. Nature 358 (1992) 149-152
37. Hamarman S., Fossella J., Ulger C., et al. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 14 (2004) 564-574
38. Cheon K., Kim B., and Cho S. Association of 4-repeat allele of the dopamine D4 receptor gene III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharamcology 32 (2007) 1377-1383
39. Sallee F, Newcorn JA, Allen AJ, et al. Pharmacogenetics of atomoxetine: relevance of DRD4. Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 23, 2004.
40. Wilson M.C. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosic Biobehav Rev 24 (2000) 51-57
41. Bobb A.J.U., Addington A.M., Sidransky E., et al. Support for association between ADHD and two candidate genes: NET1NET and DRD1. Am J Med Genet B Neuropsychiatr Genet 134 (2005) 67-72
42. Roman T., Schmitz M., Polanczyk G.V., et al. Is the α-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder?. Am J Med Genet B Neuropsychiatr Genet 120 (2003) 116-120
43. Michelson D., Faries D., Wernicke J., et al. Atomoxetine in the treatment of children and adolescent with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108 (2001) E83
44. Yang L., Wang Y.-F., Li J., et al. Association of norepinephrine transporter gene (NET) with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43 (2004) 1154-1158
45. Polanczyk G., Zeni C., Genro J.P., et al. Association of the adrenergic α2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64 (2007) 218-224
46. Patrick K.S., Straughn A.B., Minhinnett R.R., et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 81 (2007) 346-353
47. Dring L.G., Smith R.L., and Williams R.T. The metabolic fate of amphetamine in man and other species. Biochem J 116 (1970) 425-435
48. Markowitz J.S., and Patrick K.S. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 40 (2001) 753-772
49. Meyer U.A., and Zanger U.M. Molecular mechanism of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37 (1997) 269-296
50. McGough J.J., Biederman J., Greenhill L.L., et al. Pharmacokinetics of SLI381 (Adderall XR), and extended-release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 42 (2003) 684-691
51. Xie H.-G., Kim R.B., Wood A.J.J., et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41 (2001) 815-850
52. *1B5′-promoter region polymorphisms. Clin Pharmacol Ther 68 (2000) 82-91
53. Michelson D., Read H.A., Ruff D., et al. CY2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 46 (2007) 242-251
54. Waldman I.D., and Gizer I.R. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev 26 (2006) 396-432
55. Friedel S., Saar K., Demple A., et al. Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol Psychiatry 12 (2007) 923-933
56. Van der Meulen EM, Bakker SC, Pauls DL, et al. A genome-wide Quantitative Trait Locus analysis on methylphenidate response rate in Dutch sibpairs with attention-deficit/hyperactivity disorder. Scientific Proceedings of the 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Berlin, Germany, August 22, 2004.
57. Pelham W.E., and Millich R. Individual differences in response to Ritalin in class work and social behavior. In: Greenhill L.L., and Osman B. (Eds). Ritalin: theory and patient management (1991), Mary Ann Liebert, New York 203-221
58. Plizska S.R., Crismon M.L., Hughes C.W., et al. The Texas Children's Medication Algorithm Project; revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 (2006) 642-657
59. Spencer T., Biederman J., Wilens T., et al. Pharmacotherapy of attention deficit hyperactivity disorder across the lifespan. J Am Acad Child Adolesc Psychiatry 35 (1996) 409-428
60. McGough J.J., Biederman J., Wigal S., et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 44 (2005) 530-538
61. Wilens T., Pelham W., Stein M., et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42 (2003) 424-433
62. Wigal T., Greenhill L., Chuang S., et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45 (2006) 1294-1303